Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Affinity Asset Advisors LLC lifted its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 350.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 45,000 shares of the company’s stock after acquiring an additional 35,000 shares during the quarter. Affinity Asset Advisors LLC owned 4.35% of Avalo Therapeutics worth $561,000 at the end of the most recent quarter.

Separately, Ikarian Capital LLC purchased a new stake in Avalo Therapeutics during the first quarter valued at about $1,015,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Trading Up 0.8 %

AVTX opened at $9.75 on Wednesday. Avalo Therapeutics, Inc. has a 12 month low of $3.95 and a 12 month high of $52.75. The business’s 50-day moving average price is $9.82 and its 200-day moving average price is $11.18.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($14.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 306.52%. On average, equities analysts forecast that Avalo Therapeutics, Inc. will post -7.78 earnings per share for the current fiscal year.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.